TCM Biotech International Corp. (TPEX:4169)

Market Cap	3.31B
Revenue (ttm)	666.53M
Net Income (ttm)	21.01M
Shares Out	59.05M
EPS (ttm)	0.36
PE Ratio	157.39
Forward PE	28.00
Dividend	0.35 (0.63%)
Ex-Dividend Date	n/a

Volume	82,643
Average Volume	48,919
Open	56.00
Previous Close	56.00
Day's Range	53.80 - 56.20
52-Week Range	43.65 - 63.60
Beta	-0.26
RSI	60.66
Earnings Date	May 19, 2025

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company’s products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods....

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4169

Financial Performance

In 2024, TCM Biotech International's revenue was 666.53 million, a decrease of -31.26% compared to the previous year's 969.62 million. Earnings were 21.01 million, an increase of 13.12%.